openPR Logo
Press release

Huateng Pharma Highlights the Pharmaceutical Potential of N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7)

05-30-2025 12:07 PM CET | Health & Medicine

Press release from: Hunan Huateng Pharmaceutical Co., Ltd.

Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This compound has gained attention for its multifunctional properties and critical role in drug discovery and development.
N-Benzylhydroxylamine Hydrochloride features a unique nitrogen-oxygen (N-O) functional group, which enables its wide-ranging applications in medicinal chemistry, including:
Metal Chelation for Iron Overload Disorders: Its ability to form stable complexes with metal ions like Fe3+ and Cu2+ makes it a promising candidate for addressing metal-induced toxicity, particularly in diseases such as β-thalassemia.
Key Intermediate in HDAC Inhibitor Synthesis: This compound plays a crucial role in synthesizing hydroxamic acid-based histone deacetylase (HDAC) inhibitors, such as Vorinostat, an FDA-approved cancer therapy.
Potential MAO Inhibition: Its structure suggests possible use in developing monoamine oxidase (MAO) inhibitors, which are important in treating depression and neurodegenerative diseases.
Antioxidant Properties: N-Benzylhydroxylamine Hydrochloride exhibits free radical scavenging activity that may help mitigate oxidative stress implicated in Alzheimer's, Parkinson's, and cardiovascular conditions.
Antibacterial and Antiviral Applications: By chelating essential metal ions, it may inhibit bacterial growth and interfere with metal-dependent viral replication mechanisms.
NOS Modulation: Its potential to regulate nitric oxide synthase (NOS) activity presents an intriguing opportunity for managing inflammation and cardiovascular health.
The compound is also widely used as an intermediate in organic synthesis, serving as a protective group for amines and facilitating the development of structurally complex molecules.
"We are dedicated to providing high-quality chemical building blocks like N-Benzylhydroxylamine Hydrochloride to accelerate innovation in drug development," said Jack Deng, CEO of Huateng Pharma. "We believe our commitment to quality and customer support will empower researchers and companies to achieve their pharmaceutical goals more efficiently."

🔗 Product information:
https://en.huatengsci.com/product/N-Benzylhydroxylamine-hydrochloride.html

Website: https://us.huatengsci.com
Email: sales@huatengusa.com
Zip code: 410205
Telephone: +86 731 89916275
Fax: + 86 731-82251112 EXT 818
Headoffice: Building E1, Lugu Corporation Plaza, High-Tech Industrial Development Zone, Changsha City, Hunan Province, P.R.China

Hunan Huateng Pharmaceutical Co., Ltd. is a world-leading supplier of PEG derivatives and pharmaceutical intermediates, offering R&D-to-commercial scale support for global biopharmaceutical customers. Our advanced manufacturing facilities and comprehensive product portfolio help accelerate drug development and deliver innovative healthcare solutions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huateng Pharma Highlights the Pharmaceutical Potential of N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) here

News-ID: 4044184 • Views:

More Releases from Hunan Huateng Pharmaceutical Co., Ltd.

Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CPHI Japan 2025
Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CP …
Changsha, China - 18 March 2025 - Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and cutting-edge capabilities at Booth No. 4X-06, located at Tokyo Big Sight, Tokyo, Japan, from April 9th to 11th, 2025. Huateng Pharma is dedicated to providing robust support
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Changsha, China - Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma's dedication to meeting the highest regulatory standards and further strengthens its commitment to supporting
Huateng Pharma to Exhibit at CPhI Milan 2024
Huateng Pharma, a leading supplier of PEG derivatives and trusted CDMO partner, is thrilled to announce its participation in CPhI Worldwide 2024, scheduled for October 14-16 in Milan, Italy. Attendees are encouraged to visit booth #3F81, where the Huateng team will present its innovative capabilities in GMP-grade PEG derivative production, Contract Development and Manufacturing Organization (CDMO) services, and fine chemicals. Sonia Lee, Business Development Manager at Huateng Pharma, extends an invitation

All 4 Releases


More Releases for Hydrochloride

Riluzole Hydrochloride Drivers and Trends in the Riluzole Hydrochloride Market t …
The global Riluzole Hydrochloride market was valued at approximately USD 500 million in 2024 and is projected to reach around USD 750 million by 2033, growing at a compound annual growth rate (CAGR) of 5.0% from 2026 to 2033. Request a sample copy of this report at: https://www.omrglobal.com/request-sample/riluzole-hydrochloride-market Riluzole Hydrochloride Market Overview: The Riluzole Hydrochloride market is a critical segment within the pharmaceutical industry, primarily focused on the treatment of amyotrophic lateral sclerosis
Vitamin B1 (Thiamine Hydrochloride) Market
The "Vitamin B1 (Thiamine Hydrochloride) Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031.  The market was valued at USD xx.x billion In 2023. Growing Demand and Growth Potential in the Global Vitamin B1 (Thiamine Hydrochloride) Market, 2024-2031 Verified Market Research's most recent report, "Vitamin B1 (Thiamine Hydrochloride) Market: Global Industry Trends, Share, Size, Growth, Opportunity and
Guest Post: Articaine Hydrochloride Market
Articaine hydrochloride is a widely used local anesthetic in dental and minor surgical procedures. Known for its effectiveness, rapid onset, and relatively low toxicity, articaine has become a popular choice among healthcare professionals. This post delves into the articaine hydrochloride market, covering its introduction, market size, market share, evolution, market trends, and the factors driving growth. Introduction Articaine hydrochloride is a local anesthetic that belongs to the amide group of anesthetics. It
Global Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution Market …
Global Info Research announces the release of the report "Global Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029" . The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles
Global Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution Market …
Global Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution Market: Driven factors and Restrictions factors The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on
Global Raloxifene Hydrochloride Market
Raloxifene hydrochloride is an oral medication envisioned for the preclusion of osteoporosis in postmenopausal women. In addition, raloxifene hydrochloride medications are also utilized for the deduction of risk and treatment of invasive breast cancer. Raloxifene hydrochloride is sold under the brand name of Evista among all others. Key factors propelling the growth of this market are increment in the number of diseases such as osteoporosis and breast cancer coupled with